本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 说明会类型 广东驱动力生物科技集团股份有限公司(以下简称"公司")于 2023 年 8 月 28 日在北京证券交易所官方信息披露平台(http://www.bse.cn/)发布了《广东驱动力 生物科技集团股份有限公司 2023 年半年度报告》(公告编号:2023-049)，为方便 广大投资者更深入了解公司 2023 年半年度经营业绩的具体情况，加强与投资者 的互动交流，公司拟召开 2023 年半年度报告业绩说明会。 证券代码：838275 证券简称：驱动力 公告编号：2023-058 广东驱动力生物科技集团股份有限公司 2023 年半年度业绩说明会预告公告 公司保荐代表人:武长军 先生 四、 投资者参加方式 本次说明会采用网络方式召开。 二、 说明会召开的时间、地点 （一）会议召开时间：2023 年 8 月 31 日 15：00-17：00。 （二）会议召开地点 本次业绩说明会将采用网络远程的方式举行，投资者可登录全景网"投资者 关系互动平台"(ht ...

证券代码：838275 证券简称：驱动力 公告编号：2023-056 广东驱动力生物科技集团股份有限公司 关于拟修订《公司章程》公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、修订内容 根据《公司法》及《证券法》和《北京证券交易所股票上市规则（试行）》 等相关规定，公司拟修订《公司章程》的部分条款，修订对照如下： | （五）公司应当给予独立董事适当 | | | --- | --- | | 的津贴。津贴的标准应当由董事会制订 | | | 预案，股东大会审议通过，并在公司年 | | | 报中进行披露。除上述津贴外，独立董 | | | 事不应从公司及其主要股东或有利害 | | | 关系的机构和人员取得额外的、未予披 | | | 露的其他利益。 | | | （六）公司可以建立必要的独立董 | | | 事责任保险制度，以降低独立董事正常 | | | 履行职责可能引致的风险。 | | | 第一百〇七条 公司独立董事除应 | 第一百〇七条 独立董事每届任期与 | | 当具有《公司法》和其他相关法律法规、 | ...

证券代码：838275 证券简称：驱动力 公告编号：2023-055 广东驱动力生物科技集团股份有限公司 独立董事工作制度 第一章 总 则 第一条 为进一步完善公司的法人治理结构及公司董事会结构，强化对内部 董事及经理层的约束和激励机制，保护中小股东及利益相关者的利益，促进公司 的规范运作，根据《中华人民共和国公司法》（以下简称《公司法》）、《上市 公司独立董事管理办法》《北京证券交易所上市公司持续监管指引第1号——独 立董事》（以下简称《指引》）等法律、法规、规范性文件以及公司章程的有关 规定，制定本工作制度。 第二条 公司独立董事是指不在公司担任除董事及董事会专门委员会委员 以外的其他职务，并与其所受聘的上市公司及其主要股东、实际控制人不存在直 接或者间接利害关系，或者其他可能影响其进行独立客观判断关系的董事。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务。独立董事应当按 照法律、行政法规、中国证券监督管理委员会（以下简称中国证监会）规定、证 券交易所业务规则和公司章程的规定，认真履行职责，在董事会中发挥参与决策、 监督制衡、专业咨询作用，维护公司整体利益，保护中小股东合法权益。 证券代码：8382 ...

证券代码：838275 证券简称：驱动力 公告编号：2023-051 广东驱动力生物科技集团股份有限公司 （1）办公、厂房建设 13,826,081.77 募集资金存放与实际使用情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、募集资金基本情况 一、募集资金总额 60,000,000.00 二、募集资金净额 48,199,933.96 三、利息及理财收益 1,157,998.15 四、募集资金使用 28,828,027.31 1、募投项目支出 28,828,027.31 2023 年半年度，公司募集资金使用和结余情况如下： 单位：元 （2）生产设备 7,018,939.62 | （3）其他 | 7,983,005.92 | | --- | --- | | 五、尚未使用的募集资金 | 20,529,904.80 | | 1、暂时闲置募集资金大额存单 | 20,000,000.00 | | 2、垫支大额存单利息待收 | 524,550.00 | | 3、活期存款 | 5,354.80 | ...

证券代码：838275 证券简称：驱动力 公告编号：2023-054 广东驱动力生物科技集团股份有限公司 董事会专门委员会工作细则 第一章 总 则 第一条 为提高公司董事会决策的科学性，完善公司法人治理结构，根据《公 司法》、《公司章程》、《上市公司治理准则》及其他有关规定，特制定本工作细则。 第二条 公司应当在董事会中设置审计委员会，审计委员会成员应当为不在 公司担任高级管理人员的董事，其中独立董事应当过半数，并由独立董事中会计专 业人士担任召集人。 公司董事会可以根据工作需要设立战略委员会、薪酬与考核委员会、提名委员 会等专门委员会。提名委员会、薪酬与考核委员会中独立董事应当过半数并担任召 集人。 第三条 独立董事在公司董事会专门委员会中应当依照法律、行政法规、中 国证监会规定、证券交易所业务规则和公司章程履行职责。独立董事应当亲自出席 专门委员会会议，因故不能亲自出席会议的，应当事先审阅会议材料，形成明确的 意见，并书面委托其他独立董事代为出席。独立董事履职中关注到专门委员会职责 范围内的公司重大事项，可以依照程序及时提请专门委员会进行讨论和审议。 第二章 专门委员会的组成和职责 第四条 各专门委员会成 ...

证券代码：838275 证券简称：驱动力 公告编号：2023-057 广东驱动力生物科技集团股份有限公司 关于召开 2023 年第一次临时股东大会通知公告（提供网络投票） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开基本情况 （一）股东大会届次 （二）召集人 本次股东大会的召集人为董事会。 （三）会议召开的合法性、合规性 本次股东大会的召开符合《公司法》等有关法律、法规及《公司章程》的规 定。 （四）会议召开方式 本次会议采用现场投票和网络投票相结合方式召开。 （五）会议召开日期和时间 1、现场会议召开时间：2023 年 9 月 13 日 14：00-15：00。 2、网络投票起止时间：2023 年 9 月 12 日 15:00—2023 年 9 月 13 日 15:00。 登记在册的股东可通过中国证券登记结算有限责任公司（以下简称"中国结 算"）持有人大会网络投票系统对有关议案进行投票表决，为有利于投票意见的 顺利提交，请拟参加网络投票的投资者在上述时间内及早登录中国结算网上营业 厅（ ...

Business Expansion and Product Development - The company has entered the pet food market with its "Emperor's Favor Blood Nutrition Series" product line[7]. - The company is focusing on expanding its market presence and developing new products in the pet food sector[7]. - The company expanded its product application areas to include aquaculture and pet food, forming a "hematopoietic+" product matrix covering livestock, ruminants, aquaculture, and pets[39]. - The company plans to continue adjusting its product structure to meet industry demands, focusing on cost reduction and efficiency for downstream clients[58]. - The company plans to focus on market expansion and new product development in the upcoming quarters to drive future growth[120]. Financial Performance - The company achieved operating revenue of ¥82,042,133.18, an increase of 27.73% compared to the same period last year[29]. - The net profit attributable to shareholders decreased by 49.78% to ¥3,087,004.88, while the net profit after deducting non-recurring gains and losses increased by 48.98% to ¥3,218,083.53[29][37]. - The gross profit margin decreased to 15.46% from 20.35% in the previous year[29]. - The net profit for the reporting period was 3.01 million yuan, a decrease of 3.14 million yuan, or 51.01%, compared to the same period last year, primarily due to a lack of government subsidies received last year[50]. - The company reported a total comprehensive income of CNY 5,915,805.81 for the current period, contributing to the overall equity changes[142]. Assets and Liabilities - The total assets decreased by 2.83% to ¥244,849,667.29, and total liabilities decreased by 3.11% to ¥18,339,309.27[31]. - The company’s asset-liability ratio (consolidated) remained stable at 7.49% compared to 7.51% last year[31]. - The company's accounts receivable increased by 28.19% to ¥25,311,848.73, reflecting a proportional increase in sales revenue[45]. - The company's inventory decreased by 47.65% to ¥7,638,555.51, primarily due to reductions in raw materials and finished goods[45]. - The total equity at the end of the reporting period is CNY 213,182,852.15, showing a decrease from the previous period's CNY 242,391,367.38, representing a decline of approximately 12.04%[143]. Research and Development - The company obtained three new utility model patents in the first half of the year[7]. - Eight new R&D projects were initiated, focusing on areas such as ruminants and aquaculture, under the concept of "hematopoietic enhancement" technology[37]. - Research and development expenses for the first half of 2023 were ¥2,137,582.81, slightly down from ¥2,293,360.29 in the previous year[120]. Awards and Recognition - The company was recognized as a specialized and innovative small and medium-sized enterprise in Guangdong Province for 2022[7]. - The "Peach Blossom" brand eggs won the second prize at the China Egg Industry Development Annual Conference[7]. - The "Blood Milk" product received the Golden Sheep Award for technological innovation at the 2023 China Meat Sheep Industry Forum[7]. - The company was awarded the title of "Annual Cost Reduction and Efficiency Increase Service Provider" at the China Agricultural and Animal Husbandry Forum[7]. - The company is recognized as a "High-tech Enterprise" and has received provincial-level certifications for "Specialized, Refined, Characteristic, and Innovative" status[38]. Cash Flow and Investments - The cash flow from operating activities decreased significantly by 92.60% to ¥1,999,325.39[32]. - The company reported a significant decrease in cash and cash equivalents, down 75.48% to ¥3,844,799.40, primarily due to cash dividends and increased investments[44]. - The company’s investment income rose by 145.04% to ¥2,482,029.52, reflecting improved performance in investment activities[47]. - Cash inflow from sales of goods and services for the first half of 2023 was ¥87,641,471.48, an increase from ¥69,949,621.42 in the same period of 2022, representing a growth of approximately 25.3%[125]. Employment and Workforce - The company has added 16 new jobs during the reporting period, contributing to regional employment stability[68]. - The company had a total of 97 employees at the end of the reporting period, an increase of 16 from the beginning of the period[108]. - The company has 44 sales personnel at the end of the reporting period, an increase of 16 from the beginning of the period[108]. Corporate Governance and Compliance - The financial report was approved by the board of directors on August 28, 2023, ensuring compliance with governance standards[152]. - The company has not experienced any significant changes in major risks during the reporting period[71]. - The company has no significant overdue receivables or expected impairments on its financial products[63]. - The company has not reported any changes due to accounting policy adjustments or prior period error corrections in the current period[138]. Shareholder Information - Major shareholders include Liu Jinping with 33.23% and Liu Pingxiang with 21.91%, collectively holding 55.15% of the company[92]. - Shareholders holding more than 5% of the company's shares commit to not transfer or manage their shares for twelve months post-listing[85]. - The company raised a total of 60 million yuan from issuing 12 million shares, with a net amount of 48.2 million yuan after expenses[96]. Risks and Challenges - The company is facing risks from market competition due to counterfeit products that mimic its brand, which could impact sales in new markets[71]. - The company has a significant risk related to the control of shares, with two individuals holding a combined 57.52% of the shares, which may influence major decisions against the interests of minority shareholders[70]. - The company is committed to adhering to environmental regulations during its operations[68].

证券代码：838275 证券简称：驱动力 公告编号：2023-047 广东驱动力生物科技集团股份有限公司 关于接待机构投资者调研情况的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 广东驱动力生物科技集团股份有限公司（以下简称"公司"）于 2023 年 6 月 30 日接待了 8 家机构的调研，现将主要情况公告如下： 一、 调研情况 调研时间：2023 年 6 月 30 日 调研地点：公司会议室 调研形式：现场调研 调研机构：广州科方生物技术股份有限公司、益可美（广州）生态科技有限 责任公司、佛山磐砻智能科技有限公司、广东力量股权投资基金管理有限公司、 惠州爱财猫投资管理有限公司、广州瑞铂茵健康科技有限公司、广州邦讯信息系 统有限公司、北京大成（广州）律师事务所 上市公司接待人员：董事长刘平祥 董事会秘书、副总经理 刘焕良 二、 调研的主要问题及公司回复概要 问题 1：下游客户使用公司产品是否具有降本增效作用？ 回复：公司所有产品都是以为客户创造价值为目的，公司产品已在市场推广 16 年，在国内规 ...

Financial Performance - Operating revenue for the first quarter reached CNY 39,110,619.25, representing a year-on-year increase of 36.90%[10] - Net profit attributable to shareholders was CNY 1,007,104.04, down 51.40% from the same period last year[10] - The total operating revenue for Q1 2023 was CNY 39,110,619.25, an increase of 37.0% compared to CNY 28,568,911.26 in Q1 2022[58] - The total operating costs for Q1 2023 amounted to CNY 37,911,093.02, up from CNY 27,140,635.69 in Q1 2022, reflecting a growth of 39.4%[58] - The net profit for Q1 2023 was CNY 978,994.81, down 52.8% from CNY 2,072,317.04 in Q1 2022[60] - The operating profit for Q1 2023 was CNY 995,316.30, a decline of 55.5% compared to CNY 2,232,202.96 in Q1 2022[59] - The total comprehensive income for Q1 2023 was CNY 978,994.81, a decrease of 52.8% from CNY 2,072,317.04 in Q1 2022[60] - The investment income for Q1 2023 was CNY 152,837.78, down 55.5% from CNY 342,850.02 in Q1 2022[59] Cash Flow - The net cash flow from operating activities increased by 307.16% to CNY 2,737,745.79 compared to the previous year[10] - The company achieved a cash inflow from operating activities of CNY 42,795,680.06 in Q1 2023, compared to CNY 29,272,307.30 in Q1 2022[66] - Operating cash inflow for Q1 2023 was CNY 54,665,244.60, an increase from CNY 29,758,286.00 in Q1 2022, representing an 83.7% growth[67] - Cash and cash equivalents at the end of Q1 2023 were CNY 13,068,088.64, down from CNY 56,672,243.01 at the end of Q1 2022, showing a decrease in liquidity[68] - The company reported a significant increase in cash received from other operating activities, totaling CNY 11,842,880.77 in Q1 2023, compared to CNY 422,665.75 in Q1 2022[67] - The company’s total cash outflow for operating activities in Q1 2023 was CNY 51,927,498.81, compared to CNY 29,085,887.17 in Q1 2022, reflecting increased operational costs[67] Assets and Liabilities - Total assets at the end of the reporting period amounted to CNY 251,814,357.83, a decrease of 0.07% compared to the end of the previous year[10] - The company's asset-liability ratio (consolidated) was 7.05%, a slight decrease from 7.51% at the end of the previous year[10] - The total liabilities decreased to CNY 17,757,123.70 in Q1 2023 from CNY 18,927,763.76 in Q4 2022, a reduction of 6.2%[53] - The equity attributable to shareholders increased to CNY 233,857,628.91 in Q1 2023 from CNY 232,830,547.07 at the end of 2022, showing a growth of 0.4%[53] - The total current assets decreased from ¥76,087,424.31 on December 31, 2022, to ¥57,017,000.42 on March 31, 2023, indicating a reduction of about 25.1%[51] Shareholder Information - The total number of ordinary shares remained at 160,277,600, with 56.27% being freely tradable shares[17] - The company reported a total shareholding of 121,319,687 shares, with 76.3888% held by major shareholders[22] - Liu Jinping and Liu Pingxiang, as a couple, directly hold 55.14523% of the company's shares, with Liu Jinping holding 33.2349% and Liu Pingxiang holding 21.9104%[22] - The company had 4,773 ordinary shareholders at the end of the reporting period[17] Commitments and Compliance - The company has committed to strict adherence to its public commitments made during the issuance process, with measures in place for any non-fulfillment[46] - The company will not distribute dividends or transfer shares until it has fulfilled its commitments[46] - The company will compensate investors for any losses resulting from the non-fulfillment of commitments[46] - The company will disclose specific reasons for any failure to fulfill commitments on designated media[43] - The company has disclosed its commitments and has no issues with trustworthiness or investigations[26] Operational Activities - The company purchased raw materials, fuel, and power amounting to 800,000.00, with a significant increase of 29,250 compared to the previous period[29] - Research and development expenses for Q1 2023 were CNY 706,165.48, down 20.2% from CNY 885,122.06 in Q1 2022[59] - The company recorded a loss of CNY 569,156.67 from the disposal of non-current assets during the reporting period[15] Financial Position - Cash and cash equivalents decreased from ¥15,681,143.54 on December 31, 2022, to ¥13,068,088.64 on March 31, 2023, representing a decline of approximately 16.5%[51] - The company's accounts receivable decreased from ¥19,745,188.45 on December 31, 2022, to ¥17,624,801.20 on March 31, 2023, a decline of about 10.7%[51] - The company's inventory decreased from ¥14,591,954.56 on December 31, 2022, to ¥12,934,217.91 on March 31, 2023, representing a decrease of approximately 11.4%[51]

Innovation and R&D - The company received 1 national invention patent authorization for a method of preparing L-phenylalanine-L-glutamine (ZL201811569892.1) and 1 international invention patent for a water-soluble anti-stress additive for ruminants [5]. - The company emphasizes the importance of continuous investment in R&D to maintain product competitiveness in a technology-intensive industry [12]. - The company introduced three new patented technologies during the reporting period, bringing the total to 17 authorized patents [45]. - The company has established an animal hematopoietic nutrition R&D center and is collaborating with renowned universities and research institutions to enhance its R&D capabilities [133]. - The company is focusing on increasing its R&D investment to develop high-value products with independent intellectual property rights [133]. - The company has committed to increasing R&D investment to maintain its first-mover advantage in the animal blood nutrition sector, which it has pioneered for over 15 years [119]. - Research and development expenses increased by 19.23% to CNY 4.75 million, reflecting the company's commitment to innovation [66]. - The company has 13 R&D personnel, accounting for 16.22% of the total workforce, an increase from 13.68% [103]. Financial Performance - The company's revenue for 2022 was approximately ¥154.06 million, representing a year-over-year increase of 12.29% compared to ¥137.19 million in 2021 [30]. - The net profit attributable to shareholders for 2022 was approximately ¥17.40 million, a decrease of 56.52% from ¥40.02 million in 2021 [30]. - The gross profit margin for 2022 was 19.25%, down from 43.60% in 2021 [30]. - Total assets at the end of 2022 were approximately ¥251.99 million, a decrease of 9.12% from ¥277.28 million at the end of 2021 [32]. - Total liabilities increased by 35.42% to approximately ¥18.93 million in 2022, compared to ¥13.98 million in 2021 [32]. - The company's debt-to-asset ratio (consolidated) was 7.51% at the end of 2022, up from 5.04% in 2021 [32]. - The current ratio decreased significantly to 4.04 in 2022 from 15.18 in 2021, a decline of 73.39% [32]. - The net cash flow from operating activities for 2022 was ¥54,469,487.07, representing a 112.29% increase compared to ¥25,658,464.35 in 2021 [34]. - The company reported a weighted average return on net assets of 6.95% for 2022, an increase of 4.51% compared to the previous year [36]. - The company reported a significant increase in long-term deferred expenses, which rose by 876.48% to CNY 24.57 million, mainly due to increased training costs [8]. Market Position and Strategy - The company focuses on R&D-driven integration of research, production, and sales, enhancing its market position in the animal blood nutrition sector [6]. - The company is focused on expanding its market presence in the functional additives sector for livestock and aquaculture [23]. - The company plans to expand its market presence and enhance product offerings, particularly in the hematopoietic product line, which saw a revenue increase of 51.43% [75]. - The company aims to enhance its product sales efforts and develop group customers, leveraging the increasing market vitality driven by national policies [124]. - The company is in the promotion phase for several of its new products, indicating a strategic focus on market expansion and innovation [106]. - The company has successfully developed new products for ruminants, aquatic animals (shrimp, crab), and layer chickens in 2022, achieving a certain market share [121]. Risks and Challenges - The company faces risks related to market competition, including the emergence of counterfeit products that may confuse customers and affect sales [13]. - The company is facing risks from market competition due to the emergence of low-priced counterfeit products that could harm its brand image [133]. - The company has not experienced significant changes in major risks during the reporting period [12]. Corporate Governance and Compliance - The company is focused on improving its internal control systems and governance to meet the increasing regulatory requirements of the Beijing Stock Exchange [128]. - The company has committed to avoiding any form of competition with its actual controllers and has been strictly adhering to this commitment [146]. - The actual controllers have promised to avoid related party transactions and have established a decision-making system to regulate such transactions, with no related transactions occurring during the reporting period [149]. - The company has established strict fund management systems to prevent fund occupation, with the actual controller continuing to uphold these commitments [156]. Shareholder Information - The actual controllers of the company hold a combined 57.5150% of the shares, which may lead to potential conflicts of interest in decision-making [136]. - Major shareholders, including the controlling shareholder, commit to not transferring or managing their shares for twelve months post-listing, with automatic extension of lock-up period under certain conditions [154]. - The largest shareholder, Liu Jing, holds 53,268,016 shares, representing 33.23% of the total shares [166]. - Liu Ping is the second-largest shareholder with 35,117,429 shares, accounting for 21.91% [166]. - The total share capital remains unchanged at 160,277,600 shares [164]. Community Engagement and Social Responsibility - The company has contributed to local employment by hiring 41 new employees during the reporting period [118]. - The company has donated materials to support COVID-19 prevention efforts in Guangzhou in 2022 [118]. - The company benefits from tax exemptions on certain feed products and fresh egg sales, which positively impacts its financial performance [98].